Cullinan Therapeutics, Inc. SEC filings CGEM

Cullinan Therapeutics, Inc. has 466 filings in SEC EDGAR's recent list, going back to Nov 2, 2020. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.

Form Description Filed Period
DEFA14A Additional proxy material Apr 28, 2026 —
DEF 14A Proxy statement Apr 28, 2026 Apr 27, 2026
DEFA14A Additional proxy material Apr 25, 2025 —
DEF 14A Proxy statement Apr 25, 2025 Apr 24, 2025
DEFA14A Additional proxy material May 16, 2024 —
DEF 14A Proxy statement May 16, 2024 Jun 26, 2024
DEFA14A Additional proxy material Apr 21, 2023 —
DEF 14A Proxy statement Apr 21, 2023 Jun 8, 2023
DEFA14A Additional proxy material Apr 29, 2022 —
DEF 14A Proxy statement Apr 29, 2022 Jun 22, 2022
DEFA14A Additional proxy material Apr 29, 2021 —
DEF 14A Proxy statement Apr 29, 2021 Jun 25, 2021

Showing 12 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
CGEM (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Cambridge, MA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1789972
Former names
Cullinan Oncology, Inc. (until Apr 2, 2024); Cullinan Management, Inc. (until Feb 22, 2021); Cullinan Oncology, LLC (until Jan 6, 2021)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.